The Effects of Variation in the GABAA Receptor Gene on Anxious Depression are Mediated by the Functional Connectivity Between the Amygdala and Middle Frontal Gyrus
Juan Qiao,Shiwan Tao,Yurong Sun,Jiabo Shi,Yu Chen,Shui Tian,Zhijian Yao,Qing Lu
DOI: https://doi.org/10.2147/ndt.s468290
IF: 2.989
2024-09-25
Neuropsychiatric Disease and Treatment
Abstract:Juan Qiao, 1, 2 Shiwan Tao, 2 Yurong Sun, 3, 4 Jiabo Shi, 2, 5 Yu Chen, 2, 5 Shui Tian, 3, 4 Zhijian Yao, 2, 5 Qing Lu 3, 4 1 Department of Psychology, Xuzhou East Hospital Affiliated to Xuzhou Medical University, Xuzhou, People's Republic of China; 2 Department of Psychiatry, Brain Hospital Affiliated to Nanjing Medical University, Nanjing, People's Republic of China; 3 School of Biological Sciences and Medical Engineering, Southeast University, Nanjing, People's Republic of China; 4 Key Laboratory of Child Development and Learning Science, Ministry of Education, Nanjing, People's Republic of China; 5 Nanjing Brain Hospital, School of Medicine, Nanjing University, Nanjing, People's Republic of China Correspondence: Zhijian Yao, Department of Psychiatry, Brain Hospital Affiliated to Nanjing Medical University, Nanjing, 210029, People's Republic of China, Email Qing Lu, Email Background: γ-aminobutyric acid (GABA) and its main receptor, the GABA A receptor, are implicated in major depressive disorder (MDD). Anxious depression (AD) is deemed to be a primary subtype of MDD. The amygdala and the dorsolateral prefrontal cortex (DLPFC) are key brain regions involved in emotional regulation. These regions contain the most GABA A receptors. Although the GABAergic deficit hypothesis of MDD is generally accepted, few studies have demonstrated how GABA A receptor gene polymorphisms affect the functions of specific brain regions, in particular, the amygdala and the DLPFC. Methods: The sample comprised 83 patients with AD, 70 patients with non-anxious depression (NAD), and 62 healthy controls (HC). All participants underwent genotyping for polymorphisms of GABA A receptor subunit genes, followed by a resting-state fMRI scan. The HAMD-17 was used to evaluate the severity of MDD. ANOVA was performed to obtain the difference in the imaging data, GABA A receptor multi-locus genetic profile scores (MGPS), and HAMD-17 scores among three groups, then the significant differences between AD and NAD groups were identified. Mediating effect analysis was used to explore the role of functional connectivity (FC) between the amygdala and DLPFC in the association between the GABA A receptor gene MGPS and AD clinical features. Results: Compared with the NAD group, the AD group had a higher GABA A receptor MGPS. AD patients exhibited a negative correlation between the MGPS and FC of the right centromedial (CM) subregion, and the right middle frontal gyrus (MFG). A negative correlation was also observed between the MGPS and anxiety/somatic symptoms. More importantly, the right CM and right MFG connectivity mediated the association between the GABA A receptor MGPS and anxiety/somatic symptoms in patients with AD. Conclusion: The decreased FC between the right MFG and right CM subregion mediates the association between GABA A receptor MGPS and AD. Keywords: anxious depression, GABAA receptor, multi-locus genetic profile scores, dorsolateral prefrontal cortex, amygdala subregion Major depressive disorder (MDD) is a highly heterogeneous affective disorder. MDD can be divided into several subtypes, with anxious depression (AD) being the most common. In addition to depression, the AD subtype manifests as nervousness, restlessness, an inability to relax, difficulty concentrating, and a fear of losing control. Previous studies have shown that 50–65% of patients with MDD satisfy the diagnostic standard for AD. 1,2 In a previous study, compared to non-anxious depression (NAD), AD was found to be characterised by unique features, including difficulty achieving remission, greater side effects from medications, and a higher recurrence frequency. 3 Additionally, AD patients exhibit a poor response to antidepressants 4–6 and higher rates of suicidal ideation 5 and suicidal behaviour. 7,8 These unique clinical features and the associated poor prognosis of patients with AD suggest that there may be differences in the biological mechanisms of AD and NAD. 9 An understanding of the biological mechanism of AD is crucial for the early judgement of patient prognosis and the design of personalised interventions for MDD patients. γ-aminobutyric acid (GABA) is a primary inhibitory neurotransmitter in the central nervous system of mammals. It plays a role in the regulation of physiological and psychological processes. 10 GABA inhibits neurotransmission through GABA A and GABA B receptors. The current stud -Abstract Truncated-
psychiatry,clinical neurology